- Home
- AGIO vs LILA Comparison
AGIO vs LILA Comparison
Compare AGIO & LILA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGIO | LILA |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | Bermuda |
| Employees | N/A | 9000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Cable & Other Pay Television Services |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | AGIO | LILA |
|---|---|---|
| Price | $35.65 | $5.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $38.88 | $13.00 |
| AVG Volume (30 Days) | ★ 1.0M | 730.1K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $43,011,000.00 | N/A |
| Revenue This Year | $76.75 | N/A |
| Revenue Next Year | $170.73 | $7.23 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.24 | $4.77 |
| 52 Week High | $46.00 | $9.04 |
Technical Indicators
Market Signals| Indicator | AGIO | LILA |
|---|---|---|
| Relative Strength Index (RSI) | 74.22 | 35.93 |
| Support Level | $26.71 | N/A |
| Resistance Level | $36.07 | $8.51 |
| Average True Range (ATR) | 1.44 | 0.37 |
| MACD | 0.79 | -0.27 |
| Stochastic Oscillator | 98.76 | 30.78 |
Price Performance
Historical ComparisonAbout AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
About LILA Liberty Latin America Ltd.
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.